CN110692884A - 一种辅助降四高的益生菌保健饮料 - Google Patents
一种辅助降四高的益生菌保健饮料 Download PDFInfo
- Publication number
- CN110692884A CN110692884A CN201911106498.9A CN201911106498A CN110692884A CN 110692884 A CN110692884 A CN 110692884A CN 201911106498 A CN201911106498 A CN 201911106498A CN 110692884 A CN110692884 A CN 110692884A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- hyperglycemia
- probiotic
- assisting
- hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 73
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 73
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 45
- 235000013361 beverage Nutrition 0.000 title claims abstract description 35
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 34
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 29
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 29
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 25
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 25
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 25
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 14
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 14
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 13
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 13
- 241000186660 Lactobacillus Species 0.000 claims abstract description 9
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims description 15
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 235000000346 sugar Nutrition 0.000 abstract description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 6
- 229940116269 uric acid Drugs 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000008558 metabolic pathway by substance Effects 0.000 abstract description 2
- 239000011707 mineral Substances 0.000 abstract description 2
- 235000010755 mineral Nutrition 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
本发明公开了一种辅助降四高的益生菌保健饮料，其特征在于：包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10‑27%格式乳杆菌LG08、5‑22%两歧双歧杆菌、10‑27%鼠李糖乳杆菌LRa05、10‑27%植物乳杆菌Lp90、10‑27%植物乳杆菌CW006、10‑30%乳双歧杆菌。本发明筛选优质益生菌菌种进行组合配，加强物质分解、消化、吸收、利用、排泄。益生菌可以参与物质代谢，调节免疫力，效果明显，无毒副作用，促进身体对多种对身体有益的矿物质、微量元素等的吸收，修复身体受伤细胞，增强肝脏、肾脏及肠道等的代谢作用，从根本上调节身体内尿酸、血脂、血糖及胆固醇等有害成分的含量。
Description
技术领域
本发明属于益生菌保健品技术领域，具体涉及一种辅助降四高的益生菌保健饮料。
背景技术
随着人们生活水平的提高、生活节奏和生活方式的改变，日常膳食不可 避免的趋向高盐、高糖，高脂，高蛋白，由盐、鱼、肉、海鲜、饮酒、少运动而带来的现代文明病富贵病“四高”症高血压、高血糖、高血脂、高尿酸(HUA)日趋严重，“四高”症导致心脑血管疾病具有“发病率高、致残率高、死亡率高、复发率高，并发症多”形成“四高一多”的特点。高血脂可以引起血管栓塞；高血压可以引起脑出血和脑血管破裂；高血糖可以引起糖尿病；高尿酸引起的痛风性急性关节炎反复发作、痛风石沉积痛风石性慢性关节炎和关节畸形，常累及肾脏引起慢性间质性肾炎和尿酸肾结石形成。
目前，中西医均有许多药物和方法对治疗“四高”有一定的效果，但是均存在不足之处。西医治疗的方法通常是服用西药，对身体副作用很大，且治表不治根，无法根治，长期饮用容易存在药物依赖性及抗药性。中医采用中药治疗，在应用中有一定的功效，见效慢的同时也对身体有副作用，长期饮用容易导致身体虚弱，身体内脏的代谢减慢等缺点，同时中药需要熬制才能服用，饮用麻烦，很少的患者能够长期坚持服用。目前市面上也涌现了一批辅助降四高的益生菌保健饮料，这些辅助降四高的益生菌保健饮料虽然可以起到一定的降血脂、血压的作用，但是收效甚微，有些仅能在降血压或降血脂或降血糖等单方面具有较好的疗效，无法兼顾降高血压、高血糖、高血脂及高尿酸等四个方面，此外，这些辅助降四高的益生菌保健饮料中的有效成分吸收不好，长期服用，对身体仍旧存在一定的副作用，治表不治本。
发明内容
针对现有技术中的不足之处，本发明提供一种辅助降四高的益生菌保健饮料。
为了达到上述目的，本发明技术方案如下：
一种辅助降四高的益生菌保健饮料，包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10-27%格式乳杆菌LG08、5-22%两歧双歧杆菌、10-27%鼠李糖乳杆菌LRa05、10-27%植物乳杆菌Lp90、10-27%植物乳杆菌CW006、10-30%乳双歧杆菌。
进一步的，所述混合益生菌中各组成菌群的质量百分比为17%格式乳杆菌LG08、12%两歧双歧杆菌、17%鼠李糖乳杆菌LRa05、17%植物乳杆菌Lp90、17%植物乳杆菌CW006、20%乳双歧杆菌。
进一步的，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
进一步的，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。作为优选，质量比为0.8167:10。
进一步的，所述益生菌保健饮料每10mL中含有10gMCT。
本发明的原料：
（1）格式乳杆菌：能有效改变各类型过敏，包括：过敏性鼻炎、结膜炎、异位性皮肤炎、荨麻疹、食物、花粉等各种过敏症状；调整过敏体质，预防宝宝过敏。预防感冒，降低细菌及病毒（肠病毒、鼻病毒、呼吸道融合病毒）感染。长期补充能稳定肠道菌相，维持好菌多坏菌少之肠道生态，进而刺激粘膜强化免疫系统。健胃整肠，促进营养吸收提高造血功能；治疗急性腹泻、胀气、肠燥症；排出肠内毒素，延缓老化；
（2）两歧双歧杆菌：两岐双歧杆菌在人体肠内发酵后可产生乳酸和醋酸，能提高钙、磷、铁的利用率，促进铁和维生素D的吸收。双歧杆菌发酵乳糖产生半乳糖，是构成脑神经系统中脑苷脂的成分，与婴儿出生后脑的迅速生长有密切关系。双歧杆菌可以产生维生素B1、B2、B6、B12及丙氨酸、缬氨酸、天冬氨酸和苏氨酸等人体必需的营养物质；
（3）鼠李糖乳杆菌：具有高效降胆固醇，促进细胞分裂，可起到调节肠道菌群、预防和治疗腹泻、排除毒素、预防龋齿、提高机体免疫力及抗癌等重要的生理保健功能；
（4）植物乳杆菌：具有很多的保健作用，如：有一定的免疫调节作用；对致病菌有抑制作用；降低血清胆固醇含量和预防心血管疾病；维持肠道内菌群平衡；促进营养物质吸收；缓解乳糖不耐症；抑制肿瘤细胞的形成等；
（5）乳双歧杆菌：可以通过调整肠道菌群，并通过产生乙酸、乳酸等短链脂肪酸来抑制肠道腐败菌的生长和有毒代谢产物的形成，刺激肠蠕动，从而减少水分的过度吸收而缓解便秘症状；可通过调整肠道正常菌群，抑制肠道许多腐败菌生长，从而减少一些肠源性致癌物的产生；
（6）MCT：是中链甘油三酯（Medium Chain Triglycerides）的简称，是由碳链长度6-12的饱和中链脂肪酸组成的甘油三酯。医药行业中常用作溶剂、载体和乳化剂，也可以作为食品行业中香精、色素和维生素的溶剂，其具有不易被胃酸分解，易在肠道中水解的特性。天然存在于棕榈仁油、椰子油等食品和母乳中，是膳食脂肪的来源之一。作为食品添加剂，中链甘油三酯仅由饱和脂肪酸构成，凝固点低，室温下为液体，粘度小。与大豆油比较，完全是无臭、无色的透明液体。与普通的油脂和氢化油脂相比，中链甘油三酯不饱和脂肪酸的含量极低，氧化稳定性非常好，其碘值不超过0.5，MCT在高温和低温下特别稳定。
有益效果：本发明筛选优质益生菌菌种进行组合配，加强物质分解、消化、吸收、利用、排泄。益生菌可以参与物质代谢，调节免疫力，效果明显，无毒副作用，促进身体对多种对身体有益的矿物质、微量元素等的吸收，修复身体受伤细胞，增强肝脏、肾脏及肠道等的代谢作用，从根本上调节身体内尿酸、血脂、血糖及胆固醇等有害成分的含量。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解，这些实施例仅用于说明本发明，其不以任何方式限制本发明的范围。
实施例1
一种辅助降四高的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由质量百分比为17%格式乳杆菌LG08、12%两歧双歧杆菌、17%鼠李糖乳杆菌LRa05、17%植物乳杆菌Lp90、17%植物乳杆菌CW006、20%乳双歧杆菌组成。混合益生菌活菌量为3×1010 CFU/g。
实施例2
一种辅助降四高的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由质量百分比为12%格式乳杆菌LG08、22%两歧双歧杆菌、12%鼠李糖乳杆菌LRa05、12%植物乳杆菌Lp90、12%植物乳杆菌CW006、30%乳双歧杆菌组成。混合益生菌活菌量为2×1010 CFU/g。
实施例3
一种辅助降四高的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由质量百分比为10%格式乳杆菌LG08、20%两歧双歧杆菌、10%鼠李糖乳杆菌LRa05、15%植物乳杆菌Lp90、15%植物乳杆菌CW006、30%乳双歧杆菌组成。混合益生菌活菌量为2.5×1010 CFU/g。
实施例4
一种辅助降四高的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由质量百分比为27%格式乳杆菌LG08、5%两歧双歧杆菌、27%鼠李糖乳杆菌LRa05、10%植物乳杆菌Lp90、10%植物乳杆菌CW006、21%乳双歧杆菌组成。混合益生菌活菌量为2.8×1010 CFU/g。
使用效果实验：
1. 动物试验：
选取SD大鼠，随机分成实验一组、实验二组、实验三组、实验四组、空白对照组，每组有10只大鼠；实验一组至四组使用实施例1至4中的辅助降四高的益生菌保健饮料，空白对照组给予等体积的生理盐水。实验组的给药剂量为1g.kg-1.d-1。每组均喂养三个月，各组动物均于第0周和第12周的周日上午8:00取血，离心取上层血清并测定血清中的总甘油三酯、葡萄糖、总胆固醇、尿酸、低密度脂蛋白胆固醇的含量。具体结果见下表1：
表1
从上表1中，本发明的辅助降四高的益生菌保健饮料在降低四高（高血压、高血糖、 高血脂、高尿酸）方面具有显著的作用。
2. 药理实验
1）本发明的辅助降四高的益生菌保健饮料的降血糖作用
实验方法：以高糖高脂饲料诱导新西兰兔肥胖模型，然后将其随机分为四组：实施例1制备的辅助降四高的益生菌保健饮料分为3个给药组、空白对照组：低剂量即Ⅰ组0.3085g/kg、中剂量即Ⅱ组0.617g/kg、高剂量即Ⅲ组0.9255g/kg，连续喂养2个月后，空腹12h，各给药组按剂量口服后2h，分别口服蔗糖，在0h、1h、2h测新西兰兔耳缘静脉血糖值。具体结果见表2。
表2
由表2可知，本发明的辅助降四高的益生菌保健饮料具有降血糖的作用。
2）本发明的辅助降四高的益生菌保健饮料的降血脂作用
实验方法：20只大鼠基础饲料喂养7天后，根据体重和空腹血清总胆固醇(TC)水平将动物随机分为四组；7天后改高脂饲料，其中低，中，高三个剂量组大鼠以灌胃方式每日给予1ml/(kg.bw)油溶液，相当于低、中、高植物胆固醇的摄入量，实验30天后抽取空腹血样，测定血清胆固醇(TC)、甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)水平。
分组实验：实施例1制备的辅助降四高的益生菌保健饮料分为3个给药组：低剂量4.0mg/(kg.bw)、中剂量16.0mg/(kg.bw)、高剂量32.0mg/(kg.bw)三个剂量组和空白对照组，空白对照组给予基础饲料。具体结果见表3。
表3高脂饲料喂养大鼠血脂的影响(X±S，mmol/L)
由表3可知，本发明制备的辅助降四高的益生菌保健饮料具有降血脂的作用。
3）本发明的辅助降四高的益生菌保健饮料的降血压作用
观察方法：选临床这段为高血压的病例100例。年龄26-70岁，性别不限，孕妇忌用。实施例1制备的辅助降四高的益生菌保健饮料分为3个给药组：分为低（25ml），中（50ml），高（75ml）三个剂量组和空白对照组（选取轻微高血压患者且实验期间不服用降压药物）。在0天、10天、20天和30天测血压值。具体结果见表4。
表4
| 组别 | 实验例数 | 0天 | 0天 | 20天 | 30天 |
| Ⅰ组 | 25 | 196.2 | 176.9 | 173.5 | 168.2 |
| Ⅱ组 | 25 | 194.0 | 172.6 | 162.8 | 156.8 |
| Ⅲ组 | 25 | 190.4 | 171.5 | 162.7 | 154.5 |
| 空白对照组 | 25 | 155.5 | 150.5 | 152.5 | 155.5 |
从表4中可知，空白对照组在不服用降压药物的情况下，其血压不稳定；而长时间服用本发明的辅助降四高的益生菌保健饮料，其具有有效降压的作用，为见血压不稳定；而且，服用本发明制备的辅助降四高的益生菌保健饮料降压的作用与服用降压药组的效果基本一致，说明本发明制备的辅助降四高的益生菌保健饮料具有降压的作用。
Claims (6)
1.一种辅助降四高的益生菌保健饮料，其特征在于：包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10-27%格式乳杆菌LG08、5-22%两歧双歧杆菌、10-27%鼠李糖乳杆菌LRa05、10-27%植物乳杆菌Lp90、10-27%植物乳杆菌CW006、10-30%乳双歧杆菌。
2.如权利要求1所述的辅助降四高的益生菌保健饮料，其特征在于，所述混合益生菌中各组成菌群的质量百分比为17%格式乳杆菌LG08、12%两歧双歧杆菌、17%鼠李糖乳杆菌LRa05、17%植物乳杆菌Lp90、17%植物乳杆菌CW006、20%乳双歧杆菌。
3. 如权利要求1所述的辅助降四高的益生菌保健饮料，其特征在于，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
4. 如权利要求1所述的辅助降四高的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。
5.如权利要求4所述的辅助降四高的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为0.8167:10。
6.如权利要求1所述的辅助降四高的益生菌保健饮料，其特征在于，所述益生菌保健饮料每10mL中含有10gMCT。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911106498.9A CN110692884A (zh) | 2019-11-13 | 2019-11-13 | 一种辅助降四高的益生菌保健饮料 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911106498.9A CN110692884A (zh) | 2019-11-13 | 2019-11-13 | 一种辅助降四高的益生菌保健饮料 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110692884A true CN110692884A (zh) | 2020-01-17 |
Family
ID=69205927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911106498.9A Pending CN110692884A (zh) | 2019-11-13 | 2019-11-13 | 一种辅助降四高的益生菌保健饮料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110692884A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111587952A (zh) * | 2020-05-27 | 2020-08-28 | 佛山科学技术学院 | 一种降低家犬体脂沉积的益生菌添加剂 |
| CN112314943A (zh) * | 2020-10-14 | 2021-02-05 | 新食代布丁(上海)智能科技有限公司 | 一种利于减肥的复合益生菌饮品及其制备方法 |
| CN112841506A (zh) * | 2021-02-03 | 2021-05-28 | 广州悦芯科技有限公司 | 一种含益生菌的降血脂功能性方便食品及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108157973A (zh) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | 一种有益糖脂代谢功能的益生菌组合物及其制剂和应用 |
-
2019
- 2019-11-13 CN CN201911106498.9A patent/CN110692884A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108157973A (zh) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | 一种有益糖脂代谢功能的益生菌组合物及其制剂和应用 |
Non-Patent Citations (2)
| Title |
|---|
| 方曙光: "干货"2019生物发酵与营养健康•益生制品产业发展高峰论坛"专题报告：益生菌与慢性疾病健康管理", 《微康益生菌HTTPS://MP.WEIXIN.QQ.COM/S/UECPZORHYU6O-F9EJKQD9Q》 * |
| 梅奥营养（广西）卢绍欣: "梅奥MAYO营养滴剂系列简介", 《美篇HTTPS://WWW.MEIPIAN.CN/2EQIT8FF》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111587952A (zh) * | 2020-05-27 | 2020-08-28 | 佛山科学技术学院 | 一种降低家犬体脂沉积的益生菌添加剂 |
| CN112314943A (zh) * | 2020-10-14 | 2021-02-05 | 新食代布丁(上海)智能科技有限公司 | 一种利于减肥的复合益生菌饮品及其制备方法 |
| CN112841506A (zh) * | 2021-02-03 | 2021-05-28 | 广州悦芯科技有限公司 | 一种含益生菌的降血脂功能性方便食品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106266105A (zh) | 一种解酒保肝的益生菌发酵中药组合物及其制备方法和应用 | |
| CN115074274B (zh) | 含乳酸菌的组合物及其用途 | |
| CN107568736A (zh) | 解酒醒酒医学配方食品 | |
| CN110338402A (zh) | 一种复合益生菌粉及其制备方法 | |
| CN110692884A (zh) | 一种辅助降四高的益生菌保健饮料 | |
| CN111955720A (zh) | 一种产妇产后催乳特殊膳食及其制备方法 | |
| CN108968037A (zh) | 老年痴呆症全营养配方食品 | |
| WO2018133007A1 (zh) | 一种调节人体肠胃机能的饮品 | |
| GB2589967A (en) | Chinese yellow rice wine containing ingredients of mulberry leaves (morus alba L.) and silkworm pupae (bombyx mori) and production method thereof | |
| CN104187613A (zh) | 失眠全营养配方食品 | |
| CN107334156A (zh) | 催乳全营养配方食品 | |
| CN107319550A (zh) | 脑外伤全营养配方食品 | |
| CN108936607A (zh) | 慢性阻塞性肺疾病全营养配方食品 | |
| CN101496568A (zh) | 一种绿豆或豌豆膳食纤维及其生产方法 | |
| CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
| CN102511876A (zh) | 山楂红枣浓浆 | |
| CN104509915A (zh) | 一种番茄醋的制备方法 | |
| CN104187650A (zh) | 特禀体质全营养配方食品 | |
| CN108660174B (zh) | 一种抗疲劳、促进肠道益生菌增殖的芝麻生物活性肽 | |
| KR101543509B1 (ko) | 금은화 발효물을 유효성분으로 함유하는 비만, 내독소혈증 또는 대사성 질환의 예방 또는 치료용 조성물 | |
| CN111084317A (zh) | 一种保健型固体饮料及其制备方法 | |
| CN109043525A (zh) | 中风患者食用的特定全营养配方食品及其制备方法 | |
| CN109043521A (zh) | 血液病患者食用的特定全营养配方食品及其制备方法 | |
| CN104187647A (zh) | 祛痘全营养配方食品 | |
| CN110169452A (zh) | 一种含变性淀粉的助消化酸奶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200117 |
|
| RJ01 | Rejection of invention patent application after publication |